Genmab Stock-Based Compensation 2010-2025 | GNMSF
- Genmab annual stock-based compensation for 2024 was $0.105B, a 22.87% increase from 2023.
- Genmab annual stock-based compensation for 2023 was $0.085B, a 36.88% increase from 2022.
- Genmab annual stock-based compensation for 2022 was $0.062B, a 26.04% increase from 2021.